Giant Axonal Neuropathy

Giant axonal neuropathy is a rare, autosomal recessive neurodegenerative disorder caused by mutations in the GAN gene. The gene encodes gigaxonin, a protein essential for normal intermediate filament and microtubule organisation within neurons. It typically presents in early childhood and progresses relentlessly over subsequent years to decade.

The disease produces progressive peripheral neuropathy and, in the majority of affected individuals, progressive central nervous system involvement.

A characteristic clinical clue is tightly curled, kinky hair, present in the great majority of affected children. It reflects the broader intermediate filament organisational defect, which extends beyond the nervous system to affect hair keratin structure.

Pathophysiology

Loss of functional gigaxonin disrupts the normal turnover and organisation of intermediate filaments (including neurofilaments) within neurons. They accumulate pathologically, forming characteristic giant, swollen axons distended with disorganised neurofilament material, from which the condition derives its name.

This axonal pathology produces progressive dysfunction of the peripheral nervous system and, in the great majority of affected individuals, the central nervous system.

The same intermediate filament defect extends beyond neural tissue to affect keratin structure within hair. This accounts for the characteristic, distinctive tightly curled, kinky hair texture seen in the great majority of affected children, often noted from early infancy. It is a valuable, relatively specific clinical clue supporting consideration of this rare diagnosis.

• Progressive peripheral neuropathy is the earliest and most consistent manifestation. It typically presents in early childhood (generally by age three to five years) with gait disturbance, distal weakness and sensory loss, together with progressive loss of deep tendon reflexes. It reflects the underlying axonal pathology.
• Progressive central nervous system involvement develops over subsequent years in the great majority of affected individuals. Additional features include cerebellar ataxia, nystagmus, cognitive decline and, in some patients, seizures. These reflect the broader neurodegenerative process beyond the peripheral nervous system.
• The characteristic tightly curled, kinky hair is present from early infancy in the great majority of affected children. It is often distinctly different in texture from the hair of unaffected family members.
• The hair is particularly noticeable and diagnostically valuable where the child's ethnic background would not otherwise be associated with this hair texture. It is a distinctive and valuable clue supporting consideration of this specific, rare diagnosis.
• The disease follows a relentlessly progressive course, typically leading to loss of independent ambulation by adolescence. Over subsequent years, progressive, severe generalised neurological disability follows.
• Respiratory muscle involvement and associated complications are an important cause of eventual mortality, generally in early adulthood, in this severe, currently incurable condition.

• Nerve conduction studies show a severe, predominantly axonal sensorimotor peripheral neuropathy.
• Nerve biopsy, where performed, demonstrates the characteristic giant, distended axons filled with disorganised neurofilament accumulation from which this condition derives its name. This provides strong support for the diagnosis, though not entirely definitive without genetic confirmation.
• Genetic testing for GAN gene mutations provides definitive diagnostic confirmation. It is increasingly the preferred initial approach where this condition is clinically suspected, given the characteristic combination of progressive peripheral neuropathy and the distinctive kinky hair phenotype.
• Where the clinical picture is sufficiently characteristic to prompt targeted genetic testing, invasive nerve biopsy can be avoided in many cases.
• Magnetic resonance imaging of the brain, in patients with evident or evolving central nervous system involvement, may show characteristic white matter signal change and cerebellar atrophy. It supports the diagnosis and provides a baseline for monitoring disease progression.
• Given the rarity of this condition, genetic confirmation is important both for definitive diagnosis and to support accurate genetic counselling for the family. Counselling covers the autosomal recessive inheritance pattern and the associated recurrence risk for future pregnancies.

• There is no currently available disease modifying or curative treatment for giant axonal neuropathy. Management is entirely supportive and rehabilitative, addressing the progressive functional consequences of the relentlessly advancing peripheral and central neurological involvement.
• Full, multidisciplinary supportive care forms the central component of ongoing care. It includes physiotherapy and occupational therapy to maximise functional capacity and manage the progressive mobility impairment.
• Provide appropriate mobility aids and equipment as the disease progresses, including a wheelchair once independent ambulation is no longer possible. Use orthotic management for the specific pattern of distal weakness and any associated foot deformity.
• Speech and language therapy supports any associated dysarthria or swallowing difficulty.
• Proactive nutritional assessment and support address the risk of aspiration and inadequate nutritional intake as bulbar and general functional capacity declines over the disease course.
• Respiratory monitoring and, where indicated, appropriate respiratory support (including consideration of non invasive ventilation as respiratory muscle involvement progresses) address the eventual respiratory compromise characteristic of advanced disease.
• Involve full palliative care as the disease progresses toward its life limiting course.
• Gene therapy approaches specifically targeting restoration of functional gigaxonin protein expression are under active investigation. They represent a potential future therapeutic avenue for this currently incurable condition, though they remain at an experimental, clinical trial stage rather than an established, widely available treatment option.
• Genetic counselling for the family is an essential component of full family centred care. It includes discussion of the autosomal recessive inheritance pattern, recurrence risk for future pregnancies, and availability of prenatal or preimplantation genetic testing where desired.
• Connect families to relevant patient support organisations given the rarity and severity of this condition. This sits alongside the child's own ongoing multidisciplinary symptomatic and supportive management.